Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Fig. 5

Kaplan-Meier Estimate of Overall Survival. Displayed is overall survival in Arm A (Cap+Bev/Eve+Exe) and Arm B (Eve+Exe/Cap+Bev) in the ITT population. Overall survival was defined as the time from start of first-line therapy to death due to any cause. Patients without documented date of death at the end of study were censored at the last date known to be alive. N = number; OS = overall survival; CI = confidence interval; NA = not reached

Back to article page
\